Advertisement

Cancer Causes & Control

, Volume 17, Issue 8, pp 1083–1089 | Cite as

High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago Prostate Survey

  • Clareann H. Bunker
  • Joseph M. Zmuda
  • Alan L. Patrick
  • Victor W. Wheeler
  • Joel L. Weissfeld
  • Lewis H. Kuller
  • Jane A. Cauley
Original Paper

Abstract

Objective

To test the hypothesis that bone mineral density (BMD), a possible surrogate of lifetime exposure to hormone/growth factor/vitamin D/calcium exposure, is higher in prostate cancer cases than controls.

Methods

Hip BMD was measured by dual X-ray absorptiometry in 222 Afro-Caribbean screening-detected prostate cancer cases and 1,503 screened non-cases, aged 45–79, in the population-based Tobago Prostate Survey. Because possible skeletal metastases may modulate BMD, men with prostate specific antigen >20 ng/ml or highly undifferentiated tumors (Gleason score ≥8) were excluded. Mean BMD, adjusted for age and body mass index, was compared in cases and non-cases by analysis of variance. Risk across age group-specific BMD quartiles was compared using logistic regression.

Results

Overall, adjusted mean hip BMD was higher in cases (1.157 g/cm2) than non-cases (1.134 g/cm2) (p = 0.02). In men aged 60–79, prostate cancer risk was two-fold higher (OR, 2.12; 95% CI: 1.21–3.71) in the highest BMD quartile compared to the lowest. There was no association in younger men (interaction, p = 0.055).

Conclusions

High bone density is associated with prostate cancer among older men, consistent with an etiological role for lifetime exposure to factors which modulate bone density. However, other etiologies may dominate prostate cancer risk among younger men.

Keywords

Afro-Caribbean Bone mineral density Hormones Prostate cancer 

Abbreviations

BMD

Bone mineral density

BMI

Body mass index

IGFI

Insulin-like growth factor I

OR

Odds ratio

PSA

Prostate specific antigen

ANOVA

Analysis of variance

NHANES

National Health and Nutrition Examination Survey

SD

Standard deviation

CI

Confidence interval

References

  1. 1.
    Ries LAG, Eisner MP, Kosary CL, et al (eds) (2005) SEER Cancer Statistics Review, 1975–2002, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005, Table XXII-2Google Scholar
  2. 2.
    Glover Jr FE, Coffey DS, Douglas LL, et al (1998) The epidemiology of prostate cancer in Jamaica. J Urol 159:1984–1987Google Scholar
  3. 3.
    Bunker, CH, Patrick, AL, Konety, BR,  et al. 2002High prevalence of Screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate SurveyCancer Epidemiol Biomark Prev11726729Google Scholar
  4. 4.
    Ross, R, Bernstein, L, Judd, H, Hanisch, R, Pike, M, Henderson, B 1986Serum testosterone levels in healthy young black and white menJ Natl Cancer Inst764548PubMedGoogle Scholar
  5. 5.
    Wu, AH, Whittemore, AS, Kolonel, LN,  et al. 1995Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and CanadaCancer Epidemiol Biomark Prev4735741Google Scholar
  6. 6.
    Platz, EA, Rimm, EB, Willett, WC, Kantoff, PW, Giovannucci, E 2000Racial variation in prostate cancer incidence in hormonal system markers among male health professionalsJ Natl Cancer Inst9220092017PubMedCrossRefGoogle Scholar
  7. 7.
    Panz, VR, Joffe, BI, Spitz, I, Lindenberg, T, Farkas, A, Haffejee, M 2001Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white menEndocrine15213216PubMedCrossRefGoogle Scholar
  8. 8.
    Sartor, O, Zheng, Q, Eastham, JA 1999Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancerUrology53378380PubMedCrossRefGoogle Scholar
  9. 9.
    Kittles, RA, Young, D, Weinrich, S,  et al. 2001Extent of linkage disequilibrium between the androgen receptor gene CAG and GCC repeats in human populations: implications for prostate cancer riskHum Genet109253261PubMedCrossRefGoogle Scholar
  10. 10.
    Bennett, CL, Price, DK, Kim, S,  et al. 2002Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic statusJ Clin Oncol2035993604PubMedCrossRefGoogle Scholar
  11. 11.
    Chamberlain, NL, Driver, ED, Miesfeld, RL 1994The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation functionNucl Acids Res2231813186PubMedGoogle Scholar
  12. 12.
    Wang, Q, Udayakumar, TS, Vasaitis, TS, Brodie, AM, Fondell, JD 2004Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cellsJ Biol Chem2791731917328PubMedCrossRefGoogle Scholar
  13. 13.
    Albertelli, MA, Scheller, A, Brogley, M, Robins, DM 2006Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length dependent effects on physiology and tumorigenesis in miceMol Endocrinol2012481260PubMedCrossRefGoogle Scholar
  14. 14.
    Chan, JM, Stampfer, MJ, Giovanucci, E,  et al. 1998Plasma insulin-like growth factor-I and prostate cancer risk: a prospective studyScience279563566PubMedCrossRefGoogle Scholar
  15. 15.
    Stattin, P, Bylund, A, Rinaldi, S,  et al. 2000Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective studyJ Nat Cancer Inst9219101917PubMedCrossRefGoogle Scholar
  16. 16.
    Wolk, A, Mantzoros, CS, Andersson, S-O,  et al. 1998Insulin-like growth factor 1 and prostate cancer risk: a population-based, case–control studyJ Nat Cancer Inst90911915PubMedCrossRefGoogle Scholar
  17. 17.
    Shi, R, Berkel, HJ, Yu, H 2001Insulin-like growth factor-I and prostate cancer: a meta-analysisBr J Cancer85991996PubMedCrossRefGoogle Scholar
  18. 18.
    Cruickshank, JK, Heald, AH, Anderson, S,  et al. 2001Epidemiology of the insulin-like growth factor system in three ethnic groupsAm J Epidemiol54504513CrossRefGoogle Scholar
  19. 19.
    Cauley, JA, Lucas, FL, Kuller, LH, Vogt, MT, Browner, WS, Cummings, SR 1996Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research GroupJAMA27614041408PubMedCrossRefGoogle Scholar
  20. 20.
    Zmuda JM, Cauley JA, Ljung BM, Bauer DC, Cummings SR, Kuller LH. Study of Osteoporotic Fractures Research Group (2001) Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Nat Cancer Inst 93:930–936Google Scholar
  21. 21.
    Conover, CA 2000Insulin-like growth factors and the skeletonCanalis, E eds. Skeletal growth factorsLippincott Williams & WilkinsPhiladelphia USA101116Google Scholar
  22. 22.
    Wiren, KM, Orwoll, ES 1999Androgens and bone: basic aspectsOrwoll, ES eds. Osteoporosis in men: the effects of gender on skeletal healthAcademic PressSan Diego, USA211245Google Scholar
  23. 23.
    Rosen, CJ 2000IGF-I and osteoporosisClin Lab Med20591602PubMedGoogle Scholar
  24. 24.
    Parfitt, AM 1997Genetic effects on bone mass and turnover-relevance to black/white differencesJ Am Coll Nutr16325333PubMedGoogle Scholar
  25. 25.
    Zhang, Y, Kiel, DP, Ellison, RC,  et al. 2002Bone mass and the risk of prostate cancer: The Framingham StudyAm J Med113734739PubMedCrossRefGoogle Scholar
  26. 26.
    Richie, JP, Catalona, WJ, Ahmann, FR,  et al. 1993Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examinationUrology42365374PubMedCrossRefGoogle Scholar
  27. 27.
    Looker, AC, Wahner, HW, Dunn, WL,  et al. 1998Updated data on proximal femur bone mineral levels of US adultsOsteopor Internat8468489CrossRefGoogle Scholar
  28. 28.
    Cauley, J, Zmuda, JM, Patrick, A, Wheeler, VW, Hill, D, Bunker, C 2001Tobago Bone Health Study: Epidemiologic Study of high bone mineral density on a population levelJ Bone Min Res16M357Google Scholar
  29. 29.
    Nelson RL, Turyk M, Kim J, Persky V (2002) Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort. BMC Cancer 2:22 (accessed 12 March 2004 at http://www.biomedcentral.com/1471-2407/2/22)Google Scholar
  30. 30.
    Wolf, RL, Zmuda, JM, Stone, KL, Cauley, JA 2000Update on the epidemiology of osteoporosisCurr Rheumatol Rep27486PubMedGoogle Scholar
  31. 31.
    Greendale, GA, Edelstein, S, Barrett-Connor, E 1997Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo StudyJ Bone Miner Res1218331843PubMedCrossRefGoogle Scholar
  32. 32.
    Bosland, MC 2000The role of steroid hormones in prostate carcinogenesisJ Natl Cancer Inst Monogr273966PubMedGoogle Scholar
  33. 33.
    Hsing, AW, Reichardt, JKV, Stanczyk, FZ 2002Hormones and prostate cancer: current perspective and future directionsProstate52213235PubMedCrossRefGoogle Scholar
  34. 34.
    Hsing, AW, Streamson, C, Gao, Y-T, Gentzchien, E, Chang, L, Stanczyk, FZ 2001Serum levels of insulin and leptin in relation to prostate cancer risk: a population-based case–control study in ChinaJ Natl Cancer Inst93783789PubMedCrossRefGoogle Scholar
  35. 35.
    Stolk, RP, Daele, PL, Pols, HA,  et al. 1996Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study.[erratum appears in Bone. 1996; 19: 566]Bone18545549PubMedCrossRefGoogle Scholar
  36. 36.
    Peehl, DM, Stamey, TA 1986Serum-free growth of adult human prostatic epithelial cellsIn Vitro Cell Dev Biol228290PubMedGoogle Scholar
  37. 37.
    Cauley, JA, Zmuda, JM, Newman, AB,  et al. 2003Circulating levels of soluble cytokine receptors predict incident fractures in older men and women: The Health Aging and Body Composition Study (HABC)J Bone Miner Res18S84Google Scholar
  38. 38.
    Kawada, M, Ishizuka, M, Takeuchi, T 1999Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6Jpn J Cancer Res90546554PubMedGoogle Scholar
  39. 39.
    Nakajima, Y, DelliPizzi, A, Mallouh, C, Ferreri, N 1995Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell linesUrol Res23205210PubMedCrossRefGoogle Scholar
  40. 40.
    Rokhlin, OW, Gudkov, AV, Kwek, S, Glover, RA, Gewies, AS, Cohen, MB 2000p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaPOncogene1919591968PubMedCrossRefGoogle Scholar
  41. 41.
    Orwoll, ES, Bevan, L, Phipps, KR 2000Determinants of bone mineral density in older menOsteopor Internat11815821CrossRefGoogle Scholar
  42. 42.
    Nomura, AM 2001Body size and prostate cancerEpidemiol Rev23126131PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Clareann H. Bunker
    • 1
  • Joseph M. Zmuda
    • 1
  • Alan L. Patrick
    • 1
    • 2
  • Victor W. Wheeler
    • 2
  • Joel L. Weissfeld
    • 1
  • Lewis H. Kuller
    • 1
  • Jane A. Cauley
    • 1
  1. 1.Department of Epidemiology, Graduate School of Public HealthUniversity of PittsburghPittsburghUSA
  2. 2.Tobago Health Studies OfficeScarborough, TobagoTrinidad and Tobago

Personalised recommendations